The anti-AIDS drug market is currently dominated by the Mumbai based Cipla. Presently, Ranbaxy laboratories, the country's largest pharmaceutical company, is planning to enter the anti-AIDS drugs segment. According to Ranbaxy's regional director for India and west Asia, S D Kaul, the company is in a position to launch Lamivudine, Nevirapine, Aabacavir and Indinavir products in the Indian market shortly.//

Ranbaxy's subsidiary, the Hyderabad-based Vorin Laboratories which is a bulk drug manufacturer, will be formulating the drugs which will be converted to the final drug at Ranbaxy's unit at Dewas in Madhya pradesh. The company has plans for in keeping the vast opportunities for the segment offers. The anti-AIDS drug segment also witnessed the entry of many more pharmaceutical companies including GlaxoSmithKline Pharmaceuticals, Aurobindo Pharmaceuticals and Zydus Cadilla.

Recently, the US based Dade Behring diagnostic company renewed its contract with Ranbaxy, putting an end to the guesswork that the US company would convert the distribution arrangement into a financial bind. Ranbaxy has ruled out the possibility of forming a joint venture with Dade Behring for the diagnostic business, which is a part of Ranbaxy. The company's main motive is to develop this anti-viral drug rather than grab the market share.
'"/>




Page: 1
Related medicine news :

1. Medicis Pharmaceutical company enters pediatric market
2. ZYDUS enters female health care segment
3. Risk of allergy more to children staying in day care centers
4. Walk-In Health Centers Launched By The NHS For Commuters
5. Primary Care centers to provide out patient treatment
6. Free HIV Tests Brings Crowd to the Testing Centers
7. NACO to Introduce 400 Additional AIDS/HIV Screening Centers
8. NACO Inaugurates 37 Additional HIV Treatment Centers
9. Radiotherapy Centers in Scotland Undergo Inspection
10. Are call centers turning a deaf ear to potential acoustic shocks?
11. ‘For-profit Dialysis Centers’ in the Spotlight Over Anti-anemia Drug Overdoe